AVI BioPharma Announces Data Presentations for RNA-Based Duchenne Muscular Dystrophy Drug Candidate at 15th International Congre
October 11 2010 - 12:00PM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs,
today announced data presentations for AVI-4658, the Company's
investigational exon skipping therapy for the treatment of Duchenne
muscular dystrophy, at the 15th International Congress of the World
Muscle Society taking place Oct. 12-16, 2010 in Kumamoto, Japan.
Steve Shrewsbury, M.D., Chief Medical Officer and Senior Vice
President of Preclinical, Clinical and Regulatory Affairs at AVI,
will present during the oral presentation session O.15-18, New
Therapeutic Targets for Neuromuscular Disorders 2, at 11 a.m. JST
on Friday, Oct. 15. The presentation, O.16, is titled "Current
progress and preliminary results with the systemic administration
trial of AVI-4658, a novel phosphorodiamidate morpholino oligomer
(PMO) skipping dystrophin exon 51 in Duchenne muscular dystrophy
(DMD)." He will be presenting some of the final clinical data from
the recently completed study in the UK.
Dr. Sebahattin Cirak, Senior Clinical Research Fellow at the
Dubowitz Neuromuscular Centre at the UCL Institute of Child Health,
London, UK, will present during poster session 3, Therapeutic
approaches; gene therapy; cell therapy; pharmacological therapy, on
Friday, Oct. 15. The presentation, 3.08, is titled "Induction of
dystrophin in DMD patients by antisense oligonucleotide AVI-4658
restores the dystrophin glycoprotein complex." The data presented
is from the single intramuscular dose study conducted in 2008 in
London.
Dr. Shrewsbury will also present during poster session 3,
Therapeutic approaches; gene therapy; cell therapy; pharmacological
therapy, on Friday, Oct. 15. The presentation, 3.07, is titled
"Preclinical safety of AVI-4658, a phosphorodiamidate morpholino
oligomer (PMO) being developed to skip exon 51 in Duchenne muscular
dystrophy."
Dr. Francesco Muntoni, Professor of Pediatric Neurology and Head
of the Dubowitz Neuromuscular Centre at the UCL Institute of Child
Health, London, England, will present a late-breaking oral abstract
at 2 p.m. JST on Saturday, Oct. 16. The presentation is titled
"Systemic administration of AVI-4658, a Phosphorodiamidate
Morpholino Oligomer (PMO) to induce exon 51 skipping, is well
tolerated and restores dystrophin expression in Duchenne Muscular
Dystrophy (DMD) boys in a dose dependent manner."
Dr. Shrewsbury's presentations will be posted on the AVI
BioPharma Web site in the "Our Programs" section after their
respective sessions are completed.
AVI-4658 is AVI's lead drug candidate being developed as a
systemically administered treatment for a substantial subgroup of
patients with Duchenne muscular dystrophy (DMD), a genetic muscle
wasting disease caused by the absence of functional dystrophin.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of
novel RNA-based therapeutics for rare and infectious diseases, as
well as other select disease targets. Applying pioneering
technologies developed and optimized by AVI, we are able to target
a broad range of diseases and disorders through distinct RNA-based
mechanisms of action. Unlike other RNA-based approaches, our
technologies can be used to directly target both messenger RNA
(mRNA) and precursor messenger RNA (pre-mRNA) to either
down-regulate (inhibit) or up-regulate (promote) the expression of
targeted genes or proteins. By leveraging our highly differentiated
RNA antisense-based technology platform, we have built a pipeline
of potentially transformative therapeutic agents, including a
clinical stage Duchenne muscular dystrophy candidate and
anti-infective candidates for influenza and hemorrhagic fever
viruses. For more information, visit www.avibio.com.
Forward-Looking Statements and
Information
This press release contains statements that are forward-looking,
including statements about the development of AVI 4658, other
antisense-based technology and the efficacy, potency and utility of
our product candidates in the treatment of rare and infectious
diseases, and its potential to treat a broad number of human
diseases. These forward-looking statements involve risks and
uncertainties, many of which are beyond AVI's control. Known risk
factors include, among others: clinical trials may not demonstrate
safety and efficacy of any of AVI's drug candidates and/or AVI's
antisense-based technology platform; any of AVI's drug candidates
may fail in development, may not receive required regulatory
approvals, or be delayed to a point where they do not become
commercially viable. Any of the foregoing risks could materially
and adversely affect AVI's business, results of operations and the
trading price of its common stock. For a detailed description of
risks and uncertainties AVI faces, you are encouraged to review the
official corporate documents filed with filed with the Securities
and Exchange Commission. AVI does not undertake any obligation to
publicly update its forward-looking statements based on events or
circumstances after the date hereof
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jul 2023 to Jul 2024